Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells

References

• Ng M, Fleming T, Robinson M, The GBD 2013 Obesity Collaboration. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781.
   PubMed Web of Science ®Google Scholar
• Scherer PE, Hill JA. Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res. 2016;118:1703–1705.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
   PubMed Web of Science ®Google Scholar
• Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:121–124.
   PubMed Web of Science ®Google Scholar
• Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103:253–259.
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939–1945.
   PubMed Web of Science ®Google Scholar
• Avogaro A, Kreutzenberg S, Fadini G. Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. CPD. 2014;20:2387–2394.
   Web of Science ®Google Scholar
• Lei Y, Hu L, Yang G, et al. Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease – recent insights focusing on angiogenesis and neovascularization. Circ J. 2017;81:770–776.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849–870.
   PubMed Web of Science ®Google Scholar
• Xue Y, Guo T, Zou L, et al. Evodiamine attenuates P2X7-mediated inflammatory injury of human umbilical vein endothelial cells exposed to high free fatty acids. Oxid Med Cell Longev. 2018;2018:1.
   Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–426.
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101:2652–2660.
   PubMed Web of Science ®Google Scholar
• Jaimes EA, Hua P, Tian RX, et al. Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. Am J Physiol Renal Physiol. 2010;298:F125–F132.
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng X, Li X, et al. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018;113:5.
   PubMed Web of Science ®Google Scholar
• Knapp A, Czech U, Góralska J, et al. Influence of fatty acids on mitochondrial metabolism of adipocyte progenitors and endothelial cells. Arch Physiol Biochem. 2012;118:128–134.
   PubMed Web of Science ®Google Scholar
• Qi J, Yu XJ, Shi XL, et al. NF-κB blockade in hypothalamic paraventricular nucleus inhibits high-salt-induced hypertension through NLRP3 and caspase-1. Cardiovasc Toxicol. 2016;16:345–354.
   PubMed Web of Science ®Google Scholar
• Moon JS, Nakahira K, Chung KP, et al. NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages. Nat Med. 2016;22:1002–1012.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang H, Qi W, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018;9:171.
   PubMed Web of Science ®Google Scholar
• Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29:707–735.
   PubMed Web of Science ®Google Scholar
• Jo EK, Kim JK, Shin DM, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148–159.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Sarkar A, Vande Walle L, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol. 2010;185:4385–4392.
   PubMed Web of Science ®Google Scholar
• Lv H, Liu Q, Wen Z, et al. Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis. Redox Biol. 2017;12:311–324.
   PubMed Web of Science ®Google Scholar
• Cordero MD, Williams MR, Ryffel B. AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging. Trends Endocrinol Metab. 2018;29:8–17.
   PubMed Web of Science ®Google Scholar
• Wang D, Luo P, Wang Y, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 2013;62:1697–1708.
   PubMed Web of Science ®Google Scholar
• Oeseburg H, de Boer RA, Buikema H, et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. ATVB. 2010;30:1407–1414.
   Web of Science ®Google Scholar
• Ishii M, Shibata R, Kondo K, et al. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. J Biol Chem. 2014;289:27235–27245.
   PubMed Web of Science ®Google Scholar
• Jain S, Sharma B. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiol Behav. 2015;152:182–193.
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Spigoni V, Cito M, et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16:27.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tada Y, Gladson S, et al. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide induced lung injury by inhibiting endothelial-to-mesenchymal transition. Respir Res. 2017;18:177.
   PubMed Web of Science ®Google Scholar
• Zhaolin Z, Guohua L, Shiyuan W, et al. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2018;e12563.
   PubMed Web of Science ®Google Scholar